However, it remains unclear which of these approaches is more effective: local therapy combined with TKI and PD-1 inhibitors for HCC or HAIC combined with TKI and PD-1 inhibitors for HCC (36). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.